MIR5195

Summary

MIR5195 (microRNA 5195, HGNC:43526) is a microRNA gene on chromosome 14q32.33.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 100847062 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:43526
Approved symbol	MIR5195
Name	microRNA 5195
Location	14q32.33
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-5195
Ensembl gene	ENSG00000265929
Ensembl biotype	miRNA
Entrez	100847062
RNAcentral	URS00007E41AF — miRNA, 115 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000583555

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000583555 — 1 exons

Exon	Start	End
ENSE00002697448	106850885	106850999

Expression profiles

Bgee: expression breadth broad, 85 present calls, max score 98.56.

Top tissues by expression

85 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tonsil	UBERON:0002372	98.56	gold quality
lymph node	UBERON:0000029	92.80	gold quality
granulocyte	CL:0000094	90.52	gold quality
spleen	UBERON:0002106	89.71	gold quality
vermiform appendix	UBERON:0001154	89.35	gold quality
bone marrow	UBERON:0002371	84.93	gold quality
blood	UBERON:0000178	83.74	gold quality
small intestine Peyer’s patch	UBERON:0003454	83.24	gold quality
small intestine	UBERON:0002108	82.80	gold quality
leukocyte	CL:0000738	80.94	gold quality
right uterine tube	UBERON:0001302	79.75	gold quality
monocyte	CL:0000576	79.26	gold quality
mucosa of transverse colon	UBERON:0004991	78.84	gold quality
duodenum	UBERON:0002114	77.76	gold quality
intestine	UBERON:0000160	76.70	gold quality
anterior cingulate cortex	UBERON:0009835	76.59	gold quality
muscle of leg	UBERON:0001383	75.11	gold quality
right atrium auricular region	UBERON:0006631	74.98	gold quality
gastrocnemius	UBERON:0001388	74.25	gold quality
liver	UBERON:0002107	73.44	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	73.37	gold quality
rectum	UBERON:0001052	73.34	gold quality
islet of Langerhans	UBERON:0000006	73.16	gold quality
urinary bladder	UBERON:0001255	73.02	gold quality
gall bladder	UBERON:0002110	72.99	gold quality
colon	UBERON:0001155	72.84	gold quality
left coronary artery	UBERON:0001626	72.84	gold quality
metanephros cortex	UBERON:0010533	72.78	gold quality
heart	UBERON:0000948	72.41	gold quality
transverse colon	UBERON:0001157	72.30	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 14)

• miR-5195-3p suppressed proliferation and invasion of human bladder cancer cells via suppression of KLF5. (PMID:28109084)
• results demonstrate that miR-5195-3p functions as a tumor suppressor by directly modulating MYO6 expression in NSCLC cells, and may be an innovative candidate target for NSCLC therapy (PMID:30387375)
• miR-5195 modulates TGFbeta signaling pathway and affects the cell cycle progression through targeting TGFB-R1, TGFB-R2, SMAD2, SMAD3, SMAD4 transcripts (PMID:30659889)
• miR-4443 and miR-5195-3p can be considered tumor suppressors, and reductions in their expression can be associated with increased tumorigenicity and cell invasion. (PMID:30810880)
• MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer (TNBC) to paclitaxel (PTX) by downregulating EIF4A2. MiR-5195-3p expression was lower in PTX-resistant tumor tissues and PTX-resistant TNBC cell lines. Upregulation of miR-5195-3p enhanced the sensitivity of PTX-resistant TNBC cells to PTX treatment. EIF4A2 was confirmed as a potential target of miR-5195-3p. (PMID:31308851)
• Low MIR5195 expression is associated with Osteosarcoma. (PMID:31411930)
• MiR-5195-3p inhibits the proliferation of glioma cells by targeting BIRC2. (PMID:31957840)
• LncRNA ST8SIA6-AS1 promotes colorectal cancer cell proliferation, migration and invasion by regulating the miR-5195/PCBP2 axis. (PMID:32373956)
• Circ_0009910 shuttled by exosomes regulates proliferation, cell cycle and apoptosis of acute myeloid leukemia cells by regulating miR-5195-3p/GRB10 axis. (PMID:33969901)
• MicroRNA-5195-3p alleviates high glucoseinduced injury in human ARPE-19 cells by targeting GMFB. (PMID:34793551)
• Long noncoding RNA matrilineal expression gene 3 inhibits hepatocellular carcinoma progression by targeting microRNA-5195-3p and regulating the expression of forkhead box O1. (PMID:34895065)
• MiR-5195-3p functions as a tumor suppressor in prostate cancer via targeting CCNL1. (PMID:35260070)
• MiR-5195-3p functions as a tumor suppressor by targeting RHBDD1 in ovarian cancer. (PMID:36825753)
• MicroRNA-5195-3p mediated malignant biological behaviour of insulin-resistant liver cancer cells via SOX9 and TPM4. (PMID:37328795)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.